Epidemiology, diagnosis, and management of atrial fibrillation in women

International Journal of Women's Health

Volumn 7, Issue , 2015, Pages 605-614

  Poli, Daniela ^a   Antonucci, Emilia ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anticoagulants; Bleeding; Hypertension; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DABIGATRAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ATRIAL FIBRILLATION; BLOOD PRESSURE REGULATION; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CREATININE CLEARANCE; DISEASE REGISTRY; ELECTROCARDIOGRAPHY; HEART FAILURE; HEART RHYTHM; HEART RIGHT VENTRICLE OVERLOAD; HORMONE SUBSTITUTION; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INCIDENCE; NEW YORK HEART ASSOCIATION CLASS; OBESITY; OBSERVATIONAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RR INTERVAL; SEX DIFFERENCE; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK; WOMEN'S HEALTH;

EID: 84936854312     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S45925     Document Type: Review

References (111)

1. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ. Guidelines for the management of atrial fbrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31(19):2369–2429.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fbrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375.
3. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fbrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–847.
4. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fbrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–952.
5. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fbrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–953.
6. Marcus GM, Alonso A, Peralta CA, et al. European ancestry as a risk factor for atrial fbrillation in African Americans. Circulation. 2010;122(20): 2009–2015.
7. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fbrillation: European perspective. Clin Epidemiol. 2014;6: 213–220.
8. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fbril-lation: Analysis and implications. Arch Intern Med. 1995;155(5): 469–473.
9. Wagstaff AJ, Overard TF, Lip GY, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fbrillation? A systematic review and meta-analysis. QJM. 2014;107 (12):955–967.
10. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005; 26(11):1115–1140.
11. Ahmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fbrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fbrillation. Expert Rev Cardiovasc Ther. 2012;10(12):1471–1480.
12. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13(1):18–28.
13. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with frst atrial fbrillation: a 21-year community-based study. J Am Coll Cardiol. 2007;49(9):986–992.
14. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fbrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010;31(8):967–975.
15. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fbrilla-tion and futter after acute stroke and transient ischemic attack. Stroke. 2004;35(7):1647–1651.
16. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fbrillation. N Engl J Med. 2014;370(26):2478–2786.
17. Lip GY, Laroche C, Ioachim PM, et al. Prognosis and treatment of atrial fbrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J. 2014;35(47):3365–3376.
18. Humphries KH, Kerr CR, Connolly SJ, et al. New-onset atrial fbrilla-tion: sex differences in presentation, treatment, and outcome. Circulation. 2001;103(19):2365–2370.
19. Paquette M, Roy D, Talajic M, et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fbrillation. Am J Cardiol. 2000;86(7):764–768.
20. Anter E, Jessup M, Callans DJ. Atrial fbrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009; 119(18):2516–2525.
21. No authors listed. Risk factors for stroke and efficacy of antithrom-botic therapy in atrial fbrillation: Analyses of pooled data from fve randomized controlled trials. Arch Intern Med. 1994;154(13): 1449–1457.
22. van Latum JC, Koudstaal PJ, Venables GS, van Gijn J, Kappelle LJ, Algra A. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fbrillation. European Atrial Fibrillation Trial (EAFT) Study Group. Stroke. 1995;26(5):801–806.
23. Stöllberger C, Chnupa P, Kronik G, et al. Transesophageal echocar-diography to assess embolic risk in patients with atrial fbrillation. ELAT Study Group. Embolism in Left Atrial Thrombi. Ann Intern Med. 1998;128(8):630–638.
24. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger R W. Factors associated with ischemic stroke during aspirin therapy in atrial fbrilla-tion: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999;30(6):1223–1229.
25. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fbrillation in the community: the Framingham Heart Study. JAMA. 2003;290(8): 1049–1055.
26. Friberg J, Scharling H, Gadsbøll N, Truelsen T, Jensen GB; Copenhagen City Heart Study. Comparison of the impact of atrial fbrillation on the risk of stroke and cardiovascular death in women versus men (the Copenhagen City Heart Study). Am J Cardiol. 2004;94(7):889–894.
27. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fbrillation: the AnTicoagulation and Risk factors In Atrial fbrillation (ATRIA) study. Circulation. 2005;112(12):1687–1691.
28. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fbrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.
29. Dagres N, Nieuwlaat R, Vardas PE, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fbrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol. 2007;49(5):572–577.
30. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Gender differences in stroke risk of atrial fbrillation patients on oral anticoagulant treatment. Thromb Haemost. 2009;101(5): 938–942.
31. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fbrillation cohort. Stroke. 2010;41(12):2731–2738.
32. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schemes for stroke in 79,884 atrial fbrillation patients in general practice. J Thromb Haemost. 2011;9(1):39–48.
33. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fbrillation: nationwide cohort study. BMJ. 2011; 342:d124.
34. Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fbrilla-tion: a nationwide cohort study. J Thromb Haemost. 2012;10(9): 1745–1751.
35. Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fbrillation. JAMA. 2012;307(18):1952–1958.
36. Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fbrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012;344:e3522.
37. Poli D, Antonucci E, Testa S, Ageno W, Palareti G; FCSA (Italian Federation of Anticoagulation Clinics). Gender differences of bleeding and stroke risk in very old atrial fbrillation patients on VKA treatment: results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Res. 2013;131(1):12–16.
38. Madias C, Trohman RG. The link between atrial fbrillation and stroke in women. Womens Health (Lond Engl). 2011;7(3):375–382.
39. Andersson T, Magnuson A, Bryngelsson IL, et al. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fbrillation without concomitant diseases: a nationwide cohort study of 9519 patients. Int J Cardiol. 2014;177(1):91–99.
40. JCS Joint Working Group. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). Circ J. 2014;78(8):1997–2021.
41. Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fbrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99(2):295–304.
42. van Walraven C, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fbrillation and a low risk for stroke while taking aspirin. Arch Intern Med. 2003;163(8):936–943.
43. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fbrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126 (3 Suppl):429S–456S.
44. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870.
45. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Stroke risk in atrial fbrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost. 2009;101(2):367–372.
46. Poli D, Lip GY, Antonucci E, Grifoni E, Lane D. Stroke risk stratification in a “real-world” elderly anticoagulated atrial fbrillation population. J Cardiovasc Electrophysiol. 2010;22(1):25–30.
47. Poli D, Testa S, Antonucci E, Grifoni E, Paoletti O, Lip GY. Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fbrillation. Chest. 2011;140(4):918–924.
48. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fbrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fbrillation. Chest. 2010;137(2):263–272.
49. Yo u JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fbrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S–e575S.
50. Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fbrillation. Can J Cardiol. 2014;30(10):1114–1130.
51. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fbrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–2104.
52. Camm JA, Lip GY, deCaterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fbrillation: an update of the 2010 ESC Guidelines for the management of atrial fbrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747.
53. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(2):517–584.
54. Franklin S, Gustin W 4th, Wong ND, et al. Haemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96(1):308–315.
55. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation. 2003;107(3):490–497.
56. Hinderliter A, Sherwood A, Blumenthal JA, et al. Changes in hemody-namics and left ventricular structure after menopause. Am J Cardiol. 2002;89(7):830–833.
57. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006; 355(3):260–269.
58. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012;(33):1750–1757.
59. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation. 2009;119(24):3070–3077.
60. Jang SJ, Kim MS, Park HJ, et al. Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fbrillation. Heart. 2013;99(1):17–21.
61. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogen-esis in atrial fbrillation: Virchow’s triad revisited. Lancet. 2009;373 (9658):155–166.
62. Faustino A, Providência R, Barra S, et al. Which method of left atrium size quantification is the most accurate to recognize thromboembolic risk in patients with non-valvular atrial fbrillation? Cardiovasc Ultrasound. 2014;12:28.
63. No authors listed. Predictors of thromboembolism in atrial fbrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med. 1992;116(1):6–12.
64. No authors listed. Transesophageal echocardiographic correlates of thromboembolism in high risk patients with nonvalvular atrial fbril-lation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med. 1998;128(8):639–647.
65. Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fbrillation with and without underlying mitral valve disease. Heart. 2004;90(4):400–405.
66. Yamauchi K, Furui H, Taniguchi N, Sotobata I. Plasma beta-thromboglobulin and platelet factor 4 concentrations in patients with atrial fbrillation. Jpn Heart J. 1986;27(4):481–487.
67. Lip GY, Lip PL, Zarifs J, et al. Fibrin D-dimer and beta-thrombo-globulin as markers of thrombogenesis and platelet activation in atrial fbrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation. 1996;94(3):425–431.
68. Guo Y, Lip GY, Apostolakis S. Infammatory biomarkers and atrial fbrillation: potential role of infammatory pathways in the pathogenesis of atrial fbrillation-induced thromboembolism. Curr Vasc Pharmacol. Epub 2013 Oct 3.
69. Krishnamoorthy S, Khoo CW, Lim HS, et al. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a ‘real-world’ community cohort of patients with atrial fbrillation. Eur J Clin Invest. 2013;43(10):1032–1038.
70. Conway DS, Heeringa J, Van Der Kuip DA, et al. Atrial fbrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke. 2003;34(2):413–417.
71. Cove CL, Albert CM, Andreotti F, Badimon L, Van Gelder IC, Hylek EM. Female sex as an independent risk factor for stroke in atrial fbrillation: possible mechanisms. Thromb Haemost. 2014;111(3): 385–391.
72. Lip GY, Pearce LA, Chin BS, Conway DS, Hart RG. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvular atrial fbrillation. Heart. 2005;91:759–763.
73. Thambidorai SK, Parakh K, Martin DO, et al. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fbrillation. Am J Cardiol. 2004;94(6):805–807.
74. Poli D, Antonucci E, Cecchi E, et al. Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fbrillation: the role of homocysteine. Stroke. 2005;36(10): 2159–2163.
75. Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG. 2006;113(1):5–14.
76. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345(17):1243–1249.
77. Wyse DG, Waldo AL, Di Marco JP, et al. A comparison of rate control and rhythm control in patients with atrial fbrillation. N Engl J Med. 2002;347(23):1825–1833.
78. Apostolakis S, Sullivan RM, Olshansky B, Lip G Y. Hormone replacement therapy and adverse outcomes in women with atrial fbrillation: an analysis from the atrial fbrillation follow-up investigation of rhythm management trial. Stroke. 2014;45(10):3076–3079.
79. Bazzano LA, Gu D, Whelton MR, et al. Body mass index and risk of stroke among Chinese men and women. Ann Neurol. 2010;67(1): 11–20.
80. Kurth T, Gaziano JM, Rexrode KM, et al. Prospective study of body mass index and risk of stroke in apparently healthy women. Circulation. 2005;111(15):1992–1998.
81. Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D’Agostino RB, Wolf PA. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med. 2006;166(1):106–111.
82. Boden-Albala B, Sacco RL, Lee HS, et al. Metabolic syndrome and isch-emic stroke risk: Northern Manhattan Study. Stroke. 2008;39(1):30–35.
83. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med. 2003;348(26):2599–2608.
84. Lee IM, Paffenbarger RS Jr. Physical activity and stroke incidence: the Harvard Alumni Health Study. Stroke. 1998;29(10):2049–2054.
85. Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Exercise type and intensity in relation to coronary heart disease in men. JAMA. 2002;288(16):1994–2000.
86. White IR, Altmann DR, Nanchahal K. Alcohol consumption and mortality: modelling risks for men and women at different ages. BMJ. 2002;325(7357):191.
87. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA. 1993;269(2):232–236.
88. Gall SL, Donnan G, Dewey HM, et al. Sex differences in presentation, severity, and management of stroke in a population-based study. Neurology. 2010;74(12):975–981.
89. Glader EL, Stegmayr B, Norrving B, et al. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke. 2003;34(8):1970–1975.
90. Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(5):1545–1588.
91. Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospec-tively designed overviews of randomized trials. Eur Heart J. 2008; 29(21):2669–2680.
92. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123(21):2434–2506.
93. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA. 2003;289(20):2673–2684.
94. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294(4):466–472.
95. Ong KL, Tso AW, Lam KS, Cheung BM. Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension. 2008;51(4):1142–1148.
96. Rodenburg EM, Stricker BH, Visser LE. Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. Br J Clin Pharmacol. 2011;71(1):95–104.
97. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fbrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43(2):241–247.
98. Rienstra M, Van Veldhuisen DJ, Hagens VE, et al. Gender-related differences in rhythm control treatment in persistent atrial fbrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol. 2005;46(7):1298–1306.
99. Ong L, Irvine J, Nolan R, et al. Gender differences and quality of life in atrial fbrillation: the mediating role of depression. J Psychosom Res. 2006;61(6):769–774.
100. Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fbrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J. 2001;142(3):498–501.
101. Cadrin-Tourigny J, Wyse DG, Roy D, et al. Efficacy of amiodarone in patients with atrial fbrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. J Cardiovasc Electrophysiol. 2014;25(12):1306–1313.
102. Forleo GB, Tondo C, De Luca L, et al. Gender-related differences in catheter ablation of atrial fbrillation. Europace. 2007;9(8):613–620.
103. Oza NM, Baveja S, Tedrow U. Bridging the gender gap in atrial fbrillation. Expert Rev Cardiovasc Ther. 2015;13(3):317–323.
104. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005;127(6):2049–2056.
105. Sullivan RM, Zhang J, Zamba G, Lip GY, Olshansky B. Relation of gender-specific risk of ischemic stroke in patients with atrial fbrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol. 2012;110(12):1799–1802.
106. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fbrillation. N Engl J Med. 2009;361(12): 1139–1151.
107. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fbrillation. N Engl J Med. 2011;365(10): 883–889.
108. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fbrillation. N Engl J Med. 2011;365(11): 981–992.
109. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fbrillation. N Engl J Med. 2013;369(22): 2093–2104.
110. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fbrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321–328.
111. Pengo V, Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fbrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106(5):868–876.